Durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial

Simple item page
dc.conference.dateSEP 19-OCT 18, 2020
dc.conference.titleESMO Virtual Congress
dc.contributor.authorFaivre-Finn, C.
dc.contributor.authorVicente, D.
dc.contributor.authorKurata, T.
dc.contributor.authorPlanchard, D.
dc.contributor.authorPaz-Ares, L.
dc.contributor.authorVansteenkiste, J. F.
dc.contributor.authorSpigel, D. R.
dc.contributor.authorGarassino, M. C.
dc.contributor.authorReck, M.
dc.contributor.authorSenan, S.
dc.contributor.authorNaidoo, J.
dc.contributor.authorRimner, A.
dc.contributor.authorWu, Y-L.
dc.contributor.authorGray, J. E.
dc.contributor.authorOzguroglu, M.
dc.contributor.authorLee, K. H.
dc.contributor.authorNewton, M.
dc.contributor.authorWang, L.
dc.contributor.authorThiyagarajah, P.
dc.contributor.authorAntonia, S. J.
dc.contributor.authoraffiliation[Faivre-Finn, C.] Univ Manchester, Manchester, Lancs, England
dc.contributor.authoraffiliation[Faivre-Finn, C.] Christie NHS Fdn Trust, Manchester, Lancs, England
dc.contributor.authoraffiliation[Vicente, D.] Hosp Univ Virgen Macarena, Seville, Spain
dc.contributor.authoraffiliation[Kurata, T.] Kansai Med Univ Hosp, Hirakata, Osaka, Japan
dc.contributor.authoraffiliation[Planchard, D.] Gustave Roussy, Dept Med Oncol, Thorac Unit, Villejuif, France
dc.contributor.authoraffiliation[Paz-Ares, L.] Univ Complutense, Hosp Univ 12 Octubre, CiberOnc, Madrid, Spain
dc.contributor.authoraffiliation[Paz-Ares, L.] CNIO, Madrid, Spain
dc.contributor.authoraffiliation[Vansteenkiste, J. F.] Univ Hosp KU Leuven, Dept Resp Oncol, Leuven, Belgium
dc.contributor.authoraffiliation[Spigel, D. R.] Sarah Cannon Res Inst, Nashville, TN USA
dc.contributor.authoraffiliation[Spigel, D. R.] Tennessee Oncol, Nashville, TN USA
dc.contributor.authoraffiliation[Garassino, M. C.] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
dc.contributor.authoraffiliation[Reck, M.] German Ctr Lung Res, Lung Clin Grosshansdorf, Airway Res Ctr North, Grosshansdorf, Germany
dc.contributor.authoraffiliation[Senan, S.] Vrije Univ Amsterdam, Amsterdam Univ Med Ctr, Canc Ctr Amsterdam, Dept Radiat Oncol, Amsterdam, Netherlands
dc.contributor.authoraffiliation[Naidoo, J.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
dc.contributor.authoraffiliation[Naidoo, J.] Johns Hopkins Univ, Bloomberg Kimmel Inst Canc Immunotherapy, Baltimore, MD USA
dc.contributor.authoraffiliation[Naidoo, J.] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, 1275 York Ave, New York, NY 10021 USA
dc.contributor.authoraffiliation[Rimner, A.] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, 1275 York Ave, New York, NY 10021 USA
dc.contributor.authoraffiliation[Wu, Y-L.] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Dept Pulm Oncol, Guangzhou, Peoples R China
dc.contributor.authoraffiliation[Wu, Y-L.] Guangdong Acad Med Sci, Guangzhou, Peoples R China
dc.contributor.authoraffiliation[Gray, J. E.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
dc.contributor.authoraffiliation[Antonia, S. J.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
dc.contributor.authoraffiliation[Ozguroglu, M.] Istanbul Univ Cerrahpasa, Cerrahpasa Sch Med, Istanbul, Turkey
dc.contributor.authoraffiliation[Lee, K. H.] Chungbuk Natl Univ, Chungbuk Natl Univ Hosp, Coll Med, Cheongju, South Korea
dc.contributor.authoraffiliation[Newton, M.] AstraZeneca, Gaithersburg, MD USA
dc.contributor.authoraffiliation[Wang, L.] AstraZeneca, Gaithersburg, MD USA
dc.contributor.authoraffiliation[Thiyagarajah, P.] AstraZeneca, Cambridge, England
dc.contributor.funderAstraZeneca
dc.date.accessioned2025-01-07T16:00:24Z
dc.date.available2025-01-07T16:00:24Z
dc.date.issued2020-09-01
dc.identifier.doi10.1016/j.annonc.2020.08.2281
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttp://www.annalsofoncology.org/article/S0923753420423634/pdf
dc.identifier.urihttps://hdl.handle.net/10668/27553
dc.identifier.wosID573469102679
dc.issue.number4
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Virgen del Rocío
dc.organizationSAS - Hospital Universitario Virgen Macarena
dc.page.numberS1178-S1179
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titleDurvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number31
dc.wostypeMeeting Abstract

Files

Collections

SAS - Hospital Universitario Virgen del Rocío
SAS - Hospital Universitario Virgen Macarena

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía